ReviewMaterials today. Bio2025
Nanomaterial-based encapsulation of biochemicals for targeted sepsis therapy.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Multi-targeted biomimetic CeO₂-based nanoplatform for sepsis therapy via mitochondrial homeostasis.International journal of pharmaceutics: X · 2026Article
- mRNA nanotherapeutics for sepsis: immune modulation strategies and translational challenges.Journal of nanobiotechnology · 2026Review
- Comparative Kinetic Modeling and Mathematical Analysis of Monoterpene Release from Nanocarrier Systems.AAPS PharmSciTech · 2026Article
- The role of immunomodulatory nano systems in the treatment of sepsis: past, present, and future.Nanomedicine (London, England) · 2026Review
- Stratified assessment of platelets in sepsis: from dynamic counts to functional phenotypes.Frontiers in immunology · 2026Review
- Hepatorenal protective role of encapsulatedJournal of advanced veterinary and animal research · 2026Article
- Emerging Nanomedicine Strategies for Sepsis: Immunomodulation and Beyond.Research (Washington, D.C.) · 2026Article
- Repulsive guidance molecule A in the resolution of inflammation from ischemic stroke-associated pneumonia in mice.Scientific reports · 2025Article
- Deferoxamine addresses metabolic dysregulation and urinary tract infections in weight-associated gestational diabetes mellitus.European journal of medical research · 2025Article
- Progress in brucellosis immune regulation inflammatory mechanisms and diagnostic advances.European journal of medical research · 2025Review
- Immunomodulatory therapy for sepsis: from pathophysiological mechanisms to precision treatment.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a life-threatening condition characterized by complex pathophysiology, including dysregulated immune responses, excessive inflammation, and oxidative stress, often leading to multi-organ failure and high mortality rates. Traditional therapies, such as antibiotics and anti-inflammatory agents, face significant limitations due to issues like drug resistance and inadequate immune modulation. Recent advancements in nanotechnology have introduced innovative solutions by leveraging nanomaterial-based encapsulation systems for bioactive substances, including antioxidants, anti-inflammatory agents, and immunomodulators. These systems enhance the stability, bioavailability, and targeted delivery of therapeutic agents, addressing critical challenges in sepsis management. Key nanocarriers, such as lipid nanoparticles, polymer-based systems, and plant-derived exosomes, offer controlled release mechanisms and precise targeting capabilities, enabling superior therapeutic outcomes. Moreover, nanomaterials' multifunctional properties allow for simultaneous modulation of oxidative stress, inflammation, and immune responses, presenting a synergistic approach to sepsis therapy. However, challenges persist, including the potential toxicity of nanomaterials, scalability of production, and hurdles in clinical translation. This review comprehensively explores the transformative potential of nanotechnology in reshaping sepsis treatment strategies, highlighting its role in advancing precision medicine and its prospects for overcoming current therapeutic barriers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.